account_id none on file
legal_name Jasper Therapeutics, Inc.
ticker JSPR
cik 1788028
domain jaspertx.com
linkedin_company_url https://www.linkedin.com/company/jaspertherapeutics
entry_point_account_id none on file
name Jasper Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 14 executives 3 family 0
why_nownone on file
callsnone on file
filings
Prepaid travel expenses 230 103 Other prepaid expenses and current assets 255 664 Total $ 3,840 $ 5,953 10 Property and equipment, net The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands): June 30, December 31, 2026 2025 Leasehold improvements $ 2,711 $ 2,711 Lab equipment 871 1,513 Office furniture & fixtures 522 522 Computer e
filing / Aug 14, 2026 / receipt
Personnel-related costs, including employee payroll and related expenses, decreased by $3.1 million, from $3.9 million for the three months ended June 30, 2025 to $0.9 million for the three months ended June 30, 2026, primarily due to the workforce reduction as part of the corporate reorganization in 2025.
filing / Aug 14, 2026 / receipt
Employee payroll and related expenses decreased by $1.8 million, from $3.1 million for the three months ended June 30, 2025 to $1.3 million for the three months ended June 30, 2026, primarily due to the workforce reduction as part of the corporate reorganization in 2025 and a decrease in stock-based compensation expenses.
filing / Aug 14, 2026 / receipt
● our expectations regarding the anticipated benefits of our corporate reorganization, including the reduction in force, and our ability to implement and achieve the expected cost savings in connection therewith;
filing / Aug 14, 2026 / receipt
The Company routinely evaluates cost reduction measures to proactively manage cash burn, but if the Company is unable to obtain adequate financing when needed or on terms favorable or acceptable to it, the Company may be forced to take broader actions such as to delay, reduce the scope of or eliminate one or more of its research and development programs.
filing / Aug 14, 2026 / receipt
As of June 30, 2026, the Company leased approximately 25,900 square feet of laboratory and office space in Redwood City, California, under an operating lease that expires in August 2026.
filing / Aug 14, 2026 / receipt
Prepaid travel expenses 230 103 Other prepaid expenses and current assets 255 664 Total $ 3,840 $ 5,953 10 Property and equipment, net The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands): June 30, December 31, 2026 2025 Leasehold improvements $ 2,711 $ 2,711 Lab equipment 871 1,513 Office furniture & fixtures 522 522 Computer e
filing / Aug 14, 2026 / receipt
Personnel-related costs, including employee payroll and related expenses, decreased by $3.1 million, from $3.9 million for the three months ended June 30, 2025 to $0.9 million for the three months ended June 30, 2026, primarily due to the workforce reduction as part of the corporate reorganization in 2025.
filing / Aug 14, 2026 / receipt
Employee payroll and related expenses decreased by $1.8 million, from $3.1 million for the three months ended June 30, 2025 to $1.3 million for the three months ended June 30, 2026, primarily due to the workforce reduction as part of the corporate reorganization in 2025 and a decrease in stock-based compensation expenses.
filing / Aug 14, 2026 / receipt
● our expectations regarding the anticipated benefits of our corporate reorganization, including the reduction in force, and our ability to implement and achieve the expected cost savings in connection therewith;
filing / Aug 14, 2026 / receipt
The Company routinely evaluates cost reduction measures to proactively manage cash burn, but if the Company is unable to obtain adequate financing when needed or on terms favorable or acceptable to it, the Company may be forced to take broader actions such as to delay, reduce the scope of or eliminate one or more of its research and development programs.
filing / Aug 14, 2026 / receipt
As of June 30, 2026, the Company leased approximately 25,900 square feet of laboratory and office space in Redwood City, California, under an operating lease that expires in August 2026.
filing / Aug 14, 2026 / receipt
executives
| Herb Cross | Chief Financial Officer | - | receipt |
| Jeet Mahal | Chief Executive Officer | - | receipt |
| Ronald Martell | President and Chief Executive Officer | - | receipt |
familynone on file
upcoming
| 2026-11-09 | earnings call | scheduled | ir |
changes
| 2026-01-07 | Chief Executive Officer, appointed | sec_8k |
| 2023-09-25 | Chief Financial Officer, appointed | sec_8k |
| 2022-02-28 | President and Chief Executive Officer, appointed | sec_8k |
mcp_package_hint
slug jasper-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$